A diagnosis of an incurable blood cancer called multiple myeloma. Three years of aggressive therapies. More toxicity than you can imagine. In and out of remission until finally, “there is nothing more that we can do for you…”
From my diagnosis of multiple myeloma in ’94 through those fateful words in ’97, I thought my cancer was only about my cancer. The fact is that most cancer survivors don’t die from cancer. Cancer survivors die from the problems caused by the cancer itself. Or we die from problems caused by chemotherapy and radiation. A blood clot can be caused by either the multiple myeloma or by chemotherapy.
I am a long-term MM survivor and MM Cancer Coach. Learn about those conventional (FDA approved) and non-conventional therapies that can help you manage your MM and minimize collateral damage such as blood clots.
In ’98, developed a blood clot in my thigh about a year after I finished my induction therapy and autologous stem cell transplant. I developed another blood clot (in the other leg) about two years later. I live an anti-MM, anti-blood clot lifestyle through nutrition, supplementation, bone health, and mind-body therapies. Everything I do is supported by research.
When I met with my doctor about my blood clot back in ’98, he told me that the standard-of-care for a blood clot was to take a blood thinner called warfarin/coumadin. He said I would have to take warfarin/coumadin for the rest of my life. I went to my PC, searched coumadin, learned of the serious long-term side effects of this drug. I chose not to take this warfarin.
After some research I decided that I could manage my blood clot without the possibility of the side effects from long-term warfarin/coumadin use. I began supplementing with Omega-3 Fatty Acids (fish oil), Nattokinase, systemic enzymes (Wobenzym N) and curcumin . Omega-3 Fatty Acids (fish oil), Wobenzym N and curcumin have documented anti-cancer properties as well.
My clots slowly shrank and disappeared over the next few years.
Please watch the video below to learn more about the evidence-based, integrative therapies to combat treatment side effects and enhance your chemotherapy.
“Cancer-associated thrombosis accounts for almost one-fifth of all cases of venous thromboembolism (VTE) and is a leading cause of death, morbidity, delays in care, and increased costs.”
“BACKGROUND: Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is common in cancer patients and surgery is an important risk factor.”
CONCLUSIONS:A significant proportion of VTE episodes among surgical patients with cancer are diagnosed after discharge from hospital. This suggests that surgical patients with cancer are at risk for VTE beyond the immediate postoperative period.”
“PICC risks under-recognized-The name PICC stands for peripherally inserted central catheter. The IV device in the arm is a thin tube that is threaded through veins and ends near the heart. It can deliver chemotherapy, antibiotics or even liquid nutrition into the bloodstream, and makes it easy to take blood samples…”
“Purpose To provide current recommendations about the prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer…
Recommendations Most hospitalized patients with active cancer require thromboprophylaxis throughout hospitalization. Routine thromboprophylaxis is not recommended for patients with cancer in the outpatient setting. It may be considered for selected high-risk patients. Patients with multiple myeloma receiving antiangiogenesis agents with chemotherapy and/or dexamethasone should receive prophylaxis with either low–molecular weight heparin (LMWH) or low-dose aspirin”